Home › Chronic Kidney Disease › Texas › McKinney
Chronic Kidney Disease clinical trials in McKinney, TX
4 studies for Chronic Kidney Disease are looking for participants at sites in and around McKinney (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
RecruitingPhase 2
- Revival Research Institute, LLC, McKinney
- Texas Institute of Cardiology, PA, McKinney
A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)
RecruitingPhase 3
- Research Site, McKinney
Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease
RecruitingPhase 2
- Sunbeam Clinical Research, McKinney
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
RecruitingPhase 3
- Research Site, McKinney
About Chronic Kidney Disease
If your kidneys are damaged and can't filter blood easily, then you may suffer from chronic kidney disease (CKD). Read about the treatments available
More about Chronic Kidney Disease on MedlinePlus
Chronic Kidney Disease trials in other cities
- New York City, NY16 studies
- Boston, MA15 studies
- Philadelphia, PA15 studies
- Dallas, TX15 studies
- Houston, TX15 studies
- Chicago, IL12 studies
- Orlando, FL11 studies
- Atlanta, GA10 studies
- Kansas City, MO9 studies
- Durham, NC9 studies
- San Antonio, TX8 studies
- Washington, DC8 studies
Other studies in McKinney
- Heart Failure7 studies
- Type 2 Diabetes6 studies
- Asthma5 studies
- COPD5 studies
- Cardiovascular Disease4 studies
- Obesity4 studies
- Atherosclerosis3 studies
- Interstitial Lung Diseases3 studies
- Graves Disease3 studies
- Atrial Fibrillation3 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.